Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Warner-admin (talk | contribs) m (Text replacement - "Squamous cell carcinoma (SCC)" to "Cutaneous squamous cell carcinoma") |
m |
||
| Line 13: | Line 13: | ||
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
*[[Cutaneous squamous cell carcinoma]] | *[[Cutaneous squamous cell carcinoma]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Multiple myeloma]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 13:52, 23 August 2018
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Follicular lymphoma
- Melanoma
- Neuroendocrine tumors
- Renal cell carcinoma
- Cutaneous squamous cell carcinoma
Diseases for which it was used
Patient drug information
History of changes in FDA indication
- 6/4/1986: Initial FDA approval
Also known as
- Brand name: Roferon-A